Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-620-3186
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions
What is Galectin Therapeutics' stock symbol?
Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."
How were Galectin Therapeutics' earnings last quarter?
Galectin Therapeutics Inc. (NASDAQ:GALT) announced its earnings results on Friday, August, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04. View Galectin Therapeutics' Earnings History.
When is Galectin Therapeutics' next earnings date?
What price target have analysts set for GALT?
1 Wall Street analysts have issued 12-month price targets for Galectin Therapeutics' stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Galectin Therapeutics' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 169.6% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics.
What is the consensus analysts' recommendation for Galectin Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics.
Has Galectin Therapeutics been receiving favorable news coverage?
News coverage about GALT stock has been trending negative on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Galectin Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Galectin Therapeutics.
Who are some of Galectin Therapeutics' key competitors?
Some companies that are related to Galectin Therapeutics include Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), G1 Therapeutics (GTHX), Eagle Pharmaceuticals (EGRX), Spectrum Pharmaceuticals (SPPI), Dova Pharmaceuticals (DOVA), Endo International (ENDP), CannTrust (CNTTF), Emisphere Technologies (EMIS), ZEALAND PHARMA/S (ZEAL), Cara Therapeutics (CARA) and Omeros (OMER).
What other stocks do shareholders of Galectin Therapeutics own?
Who are Galectin Therapeutics' key executives?
Galectin Therapeutics' management team includes the folowing people:
- Dr. Harold H. Shlevin, Pres & CEO (Age 69)
- Mr. Jack W. Callicutt, CFO & Sec. (Age 52)
- Robert Tritt, Gen. Counsel
- Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)
- Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49)
How do I buy shares of Galectin Therapeutics?
Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Galectin Therapeutics' stock price today?
One share of GALT stock can currently be purchased for approximately $4.08.
How big of a company is Galectin Therapeutics?
Galectin Therapeutics has a market capitalization of $231.05 million. The company earns $-13,900,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.View Additional Information About Galectin Therapeutics.
What is Galectin Therapeutics' official website?
How can I contact Galectin Therapeutics?
Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]
MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.
